One study in advanced gastric cancer treated with pembrolizumab as ≥ 2nd-line therapy has provided clinical evidence showing that all EBV ( +) gastric cancer (6 of 61, 9.8%) exhibited ORR of 100% and tumor PD-L1 CPS (≥ 1%) [24]. Here, CD274 is linked to gastric cancer.